Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George Sledge

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Clinical Breast Cancer|June 9, 2019
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-offJenica N Upshaw, Robin Ruthazer, Kathy D Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusRaymond Tubbs, William E Barlow, G Thomas Budd, et al.
The American Journal of Pathology|February 13, 2010
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeMalini Harigopal, William E Barlow, Greg Tedeschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Cancers|April 27, 2024
The Genomic, Transcriptomic, and Immunologic Landscape of <i>HRAS</i> Mutations in Solid TumorsSamuel A Kareff, Asaad Trabolsi, Harris B Krause, et al.
Breast Cancer Research and Treatment|September 20, 2024
Genomic and transcriptomic landscape of HER2-low breast cancerRani Bansal, Tolulope Adeyelu, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Clinical Breast Cancer|June 9, 2019
Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-offJenica N Upshaw, Robin Ruthazer, Kathy D Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2009
Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusRaymond Tubbs, William E Barlow, G Thomas Budd, et al.
The American Journal of Pathology|February 13, 2010
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcomeMalini Harigopal, William E Barlow, Greg Tedeschi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancerMartine J Piccart-Gebhart, Tomasz Burzykowski, Marc Buyse, et al.
Cancers|April 27, 2024
The Genomic, Transcriptomic, and Immunologic Landscape of <i>HRAS</i> Mutations in Solid TumorsSamuel A Kareff, Asaad Trabolsi, Harris B Krause, et al.
Breast Cancer Research and Treatment|September 20, 2024
Genomic and transcriptomic landscape of HER2-low breast cancerRani Bansal, Tolulope Adeyelu, Andrew Elliott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 19, 2008
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancerTomasz Burzykowski, Marc Buyse, Martine J Piccart-Gebhart, et al.
JCO Oncology Advances|May 7, 2025
Multiomic Characterization of <i>RCC1</i> and <i>RCC2</i> Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer OutcomesMisako Nagasaka, Brian Warnecke, Sai-Hong Ignatius Ou, et al.
BMC Cancer|March 13, 2025
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancerMingli Yang, Michael V Nebozhyn, Michael J Schell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Edith A Perez, Edward H Romond, Vera J Suman, et al.
Pageof 4